AMYDA

Disentangling the contributions of dopamine and amyloid burden to age-related changes in cognition and brain network connectivity in healthy older adults

Coordinatore	UMEA UNIVERSITET    more  Organization address address: UNIVERSITETOMRADET city: UMEA postcode: 901 87 contact info Titolo: Prof. Nome: Lars Cognome: Nyberg Email: send email Telefono: +46 90 7866429
Nazionalità Coordinatore	Sweden [SE]
Totale costo	258˙766 €
EC contributo	258˙766 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2011-IOF
Funding Scheme	MC-IOF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-04-01   -   2016-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UMEA UNIVERSITET  Organization address address: UNIVERSITETOMRADET city: UMEA postcode: 901 87 contact info Titolo: Prof. Nome: Lars Cognome: Nyberg Email: send email Telefono: +46 90 7866429	SE (UMEA)	coordinator	258˙766.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Normal aging is associated with declines in episodic memory and executive functions. Research suggests that around 20-50% of clinically healthy individuals show significant accumulation of amyloid, one of the hallmark biomarkers of Alzheimer’s disease but it has been difficult to establish the functional impact of amyloid burden in healthy older adults. Decreases in dopaminergic functioning in old age have been shown to mediate age-related changes in various cognitive domains. This project uses state-of-the-art positron emission tomography, functional magnetic resonance imaging and sensitive neuropsychological testing to disentangle the functional impact of amyloid pathology from those of dopaminergic effects on cognition in clinically healthy older individuals. It is hypothesized that dopamine and amyloid burden will have dissociable effects on cognition and brain network connectivity. The results of the proposed project will have important implications for characterizing the early preclinical phase of Alzheimer’s disease and aid the development of strategies for early identification of incipient neuropathological processes. The research will take place during the 24-months outgoing phase at Harvard University and Massachusetts General Hospital in Boston, MA, USA, and be followed by a 12-months reintegration phase at the Umeå Center for Functional Brain Imaging in Sweden. This IOF will lead to new insights into the neurobiological processes of cognitive aging and early Alzheimer’s disease, contribute to the accumulation of scientific skills and excellence in Europe, and enhance the career opportunities of a young female researcher in Europe.'